Guzman Carlos A, Borsutzky Stefan, Griot-Wenk Monika, Metcalfe Ian C, Pearman Jon, Collioud Andre, Favre Didier, Dietrich Guido
Vaccine Research Group, Division of Microbiology, GBF-German Research Centre for Biotechnology, Mascheroder Weg 1, Braunschweig, Germany.
Vaccine. 2006 May 1;24(18):3804-11. doi: 10.1016/j.vaccine.2005.07.111. Epub 2005 Sep 19.
Because of high infectivity and significant disease burden, typhoid fever constitutes a major global health problem. Implementation of adequate food handling practices and establishment of safe water supplies are the cornerstone for the development of an effective prevention program. However, vaccination against typhoid fever remains an essential tool for the effective management of this disease. Currently, there are two well tolerated and effective licensed vaccines. One is based on defined subunit virulence (Vi) polysaccharide antigen and can be administered either intramuscularly or subcutaneously and the other is based on the use of live attenuated bacteria for oral administration. The advantages and disadvantages of the various approaches taken in the development of a vaccine against typhoid fever are discussed, along with the potential for future vaccine candidates.
由于伤寒具有高传染性和重大疾病负担,它构成了一个主要的全球健康问题。实施适当的食品处理措施和建立安全的供水系统是制定有效预防计划的基石。然而,伤寒疫苗接种仍然是有效管理这种疾病的一项重要工具。目前,有两种耐受性良好且有效的许可疫苗。一种基于确定的亚单位毒力(Vi)多糖抗原,可通过肌肉注射或皮下注射给药,另一种基于使用减毒活细菌进行口服给药。文中讨论了开发伤寒疫苗所采用的各种方法的优缺点,以及未来候选疫苗的潜力。